...November 16, 2023 - Higher costs to strengthen quality assurance and legal regulation increase the prospect of lower profitability over the next year or two than previously assumed. - We therefore revised to stable from positive our outlook on Olympus Corp., and we also affirmed our '###+' long-term ratings on the company and its debt. - The stable outlook reflects our view that the company will steadily strengthen its ability to generate earnings with a focus on medical device business and will maintain sound financial standing. TOKYO (S&P Global Ratings) Nov. 16, 2023--S&P Global Ratings today said it has revised to stable from positive its outlook on Japan-based medical device company Olympus Corp. We also affirmed our '###+' long-term issuer credit and senior unsecured issue ratings on the company and its debt. The change in outlook reflects our expectation that expenses to strengthen Olympus' quality assurance and regulatory affairs (QARA) framework will expand in the next three years....
